Method of regulating biological activity of pituitary tumor transforming gene (PTTG)1 using PTTG2
Disclosed is a method of inhibiting neoplastic cellular proliferation and/or transformation of mammalian breast or ovarian cells, including cells of human origin, in vitro or in vivo. The inventive method involves the use of a pituitary tumor transforming gene (PTTG)2 peptide, which has the ability to regulate endogenous PTTG1 expression and/or function in a dominant negative manner. In some embodiments, the invention is directed to gene-based treatments that deliver PTTG2-encoding polynucleotides to mammalian cells, whether in vitro or in vivo, to inhibit the endogenous expression of PTTG1. Other embodiments are directed to peptide-based treatments that deliver PTTG2 peptide molecules to the cells, which inhibit endogenous PTTG1 expression and/or PTTG1 function. Kits useful in practicing the inventive method are also disclosed.
1. A method of inhibiting neoplastic cellular proliferation or transformation of both, in vitro is comprising:
providing a mammalian cell, in vitro, that endogenously overexpresses PTTG1; and
delivering to a mammalian cell a composition comprising an expression vector comprising a promoter and a polynucleotide, said polynucleotide comprising a first DNA segment encoding a mammalian PTTG2 peptide consisting of amino acid residues 1-191 of SEQ ID NO:64, said polynucleotide being operatively linked to the promoter in a transcriptional unit,
said expression vector being complexed with a cellular uptake-enhancing agent, in an amount and under conditions sufficient to enter the cell, such that the PTTG2 peptide is expressed in the cell,
whereby neoplastic cellular proliferation or transformation or both, of the cell is inhibited.
2. The method of claim 1 , wherein the polynucleotide further comprises a second DNA segment encoding an uptake-enhancing and/or importation-competent, or both, peptide segment.
3. The method of claim 2 , wherein the cellular uptake-enhancing or importation-competent, or both, peptide segment is a human immunodeficiency virus TAT-derived peptide segment, a signal peptide from Kaposi fibroblast growth factor, ferritin peptide, or lactalbumin-α peptide.
4. The method of claim 1 , wherein the cell is of human origin.
5. The method of claim 1 , wherein the cell exhibits neoplastic, hyperplastic, cytologically dysplastic, or premalignant cellular growth or proliferation.
6. The method of claim 1 , wherein the cell is a malignant cell.
7. The method of claim 1 , wherein the the cell is pituitary cell, a colon cell, leukocyte, a breast cell, or an ovarian cell.
8. The method of claim 1 , wherein said uptake-enhancing agent comprises a lipid agent.
9. The method of claim 1 , wherein the composition in vitro that endogenously overexpresses PTTG1, and in which neoplastic cellular proliferation or transformation, or both, is inhibited, comprising:
a composition comprising an expression vector comprising a promoter and a polynucleotide, said polynucleotide comprising a first DNA segment encoding a mammalian PTTG2 peptide consisting of amino acid residues 1-191 of SEQ ID NO:64, said polynucleotide being operatively linked to the promoter in a transcriptional unit,
said expression vector being complexed with a cellular uptake-enhancing agent, in an amount and under conditions sufficient to enter the cell, such that the PTTG2 peptide is expressed in the cell.
10. The mammalian cell of claim 9 , wherein the polynucleotide further comprises a second DNA segment encoding an uptake-enhancing or importation-competent, or both, peptide segment.
11. The mammalian cell of claim 10 , wherein the cellular uptake-enhancing or importation-competent, or both, peptide segment is a human immunodeficiency virus TAT-derived peptide segment, a signal peptide from Kaposi fibroblast growth factor, ferritin peptide, or lactalbumin-α peptide.
12. The mammalian cell of claim 9 , wherein the cell is of human origin.
13. The method of claim 9 , wherein the cell exhibits neoplastic, hyperplastic, cytologically dysplastic, or premalignant cellular growth or proliferation.
14. The mammalian cell of claim 9 , wherein the cell is a malignant cell.
15. The mammalian cell of claim 9 , wherein the cell is a pituitary cell, a colon cell, a leukocyte cell, a breast cell, or a ovarian cell.
16. The mammalian cell of claim 9 , wherein said uptake-enhancing agent comprises a lipid agent.